文献速递瓣膜病与结构性心脏病

经导管三尖瓣环成形术早期可行性研究:SCOUT试验30天结果

Early Feasibility Study of a Transcatheter Tricuspid Valve Annuloplasty: SCOUT Trial 30-Day Results.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

SCOUT试验为前瞻性单臂多中心早期可行性研究,纳入15例NYHA≥II级且中重度以上功能性三尖瓣反流患者,评估新型经导管三尖瓣环成形装置。30天技术成功率80%,3例单垫片环脱离未再干预;12例完成装置植入者三尖瓣环面积和有效反流口面积显著减小,左室每搏量显著增加,意向治疗人群NYHA分级、MLHFQ和6MWT显著改善。

要点

  • 15例功能性三尖瓣反流患者植入新型经导管三尖瓣环成形装置,30天无死亡、卒中、出血、心包填塞或瓣膜再干预。
  • 30天技术成功率80%,3例发生单垫片环脱离但未再干预。
  • 12例完成植入者三尖瓣环面积和有效反流口面积显著减小,左室每搏量显著增加。

核心结论

  • SCOUT试验30天结果证实新型经导管装置安全性,可减小三尖瓣环面积和有效反流口面积、增加左室每搏量并改善生活质量。

研究设计与样本

  • 前瞻性、单臂、多中心早期可行性研究,2015年11月至2016年6月纳入15例NYHA功能分级≥II级且中重度以上功能性三尖瓣反流患者。

主要发现

  • 全部患者(平均73.2±6.9岁,87%女性)成功植入装置,无死亡、卒中、出血、心包填塞或瓣膜再干预。
  • 30天技术成功率为80%,3例发生单垫片环脱离且未再干预。
  • 剩余12例患者三尖瓣环面积从12.3±3.1 cm2降至11.3±2.7 cm2(p=0.019),有效反流口面积从0.51±0.18 cm2降至0.32±0.18 cm2(p=0.020)。
  • 剩余12例患者左室每搏量从63.6±17.9 ml增至71.5±25.7 ml(p=0.021)。
  • 意向治疗人群NYHA功能分级改善≥1级(p=0.001),MLHFQ从47.4±17.6降至20.9±14.8(p<0.001),6MWT从245.2±110.1 m增至298.0±107.6 m(p=0.008)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The SCOUT (Percutaneous Tricuspid Valve Annuloplasty System for Symptomatic Chronic Functional Tricuspid Regurgitation) trial is a prospective, single-arm, multicenter, early feasibility study of a novel transcatheter device to plicate the tricuspid annulus (TA) and reduce tricuspid regurgitation (TR). OBJECTIVES: This study tested the feasibility and safety of a novel transcatheter device and assessed its early performance and functional outcomes. METHODS: Between November 2015 and June 2016, 15 patients with New York Heart Association (NYHA) functional class ≥II and moderate or greater functional TR were enrolled. Primary performance and safety endpoint outcomes were technically successful at 30 days with no reintervention. Echocardiographic measurements (TA diameter, effective regurgitant orifice area [EROA], left ventricular stroke volume [LVSV]) and quality-of-life (QoL) measurements (NYHA functional class, Minnesota Living with Heart Failure Questionnaire [MLHFQ], and 6-min walk test [6MWT]) were performed at baseline and 30 days. RESULTS: All patients (mean 73.2 ± 6.9 years of age, 87% female) underwent successful device implantation with no deaths, strokes, bleeding, tamponade, or valve reintervention. Technical success rate at 30 days was 80%, with 3 single-pledget annular detachments without reintervention. In the remaining 12 patients, there were significant reductions in TA (12.3 ± 3.1 cm2 to 11.3 ± 2.7 cm2, respectively; p = 0.019) and EROA (0.51 ± 0.18 cm2 vs. 0.32 ± 0.18 cm2, respectively; p = 0.020), with significant increase in LVSV (63.6 ± 17.9 ml vs. 71.5 ± 25.7 ml, respectively; p = 0.021). In the intention-to-treat cohort, there were significant improvements in NYHA functional class (≥1 class, p = 0.001), MLHFQ (47.4 ± 17.6 to 20.9 ± 14.8; p < 0.001), and 6MWT (245.2 ± 110.1 to 298.0 m ± 107.6 m; p = 0.008). CONCLUSIONS: The 30-day results of the SCOUT trial confirmed the safety of the novel transcatheter device, which reduced TA and EROA, increased LVSV, and improved QoL. (Early Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) Also Known as TriAlign [SCOUT]; NCT02574650.).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Hahn RT, Meduri CU, Davidson CJ, et al. Early Feasibility Study of a Transcatheter Tricuspid Valve Annuloplasty: SCOUT Trial 30-Day Results. J Am Coll Cardiol. 2017. PMID: 28385308. doi:10.1016/j.jacc.2017.01.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。